The Company Rewriting How DNA Is Made

DNA, written to order

Every gene therapy, mRNA vaccine, CRISPR experiment, and engineered microbe begins with a single practical need: a specific sequence of DNA that has to exist as a physical molecule. For decades, obtaining that molecule meant chemical synthesis pipelines dating to the 1980s - methods that top out around 10 kilobases, choke on repetitive or GC-rich sequences, and force researchers to stitch fragments together by hand.

Ansa Biotechnologies takes a different route. Its proprietary platform uses engineered enzymes - built on terminal deoxynucleotidyl transferase (TdT) chemistry, the same enzyme class immune cells use - to add nucleotides one at a time, directly, with no assembly step. The result is a service that produces custom DNA that is longer, more complex, and higher-fidelity than what conventional providers can reliably deliver.

The company's tagline sums up the ambition plainly: "Expect More from Your DNA." In practice that means sequences other vendors decline to make, delivered on a clock the customer can plan around.

From the bench to biomanufacturing

Ansa's customers are the scientists and R&D teams for whom DNA is a raw material: biopharmaceutical developers building new therapeutics and diagnostics, gene and cell therapy groups, vaccine researchers, and industrial and agricultural biotech firms. The common thread is that these teams were previously blocked - waiting on, or turned away by, legacy synthesis.

Customer testimonials point to the same relief: Ansa made constructs "other companies had declined," and for some, "synthesis is no longer the bottleneck."

B2B, sold on trust

Ansa is a business-to-business custom manufacturer. It sells synthetic DNA products - clonal DNA, fragments, vectors - and bespoke synthesis services, competing not on price alone but on the things researchers actually get stuck on: sequence complexity, length, fidelity, and guaranteed turnaround.

The Series B explicitly funds scaling US-based DNA manufacturing, positioning Ansa as a domestic supplier at a moment when supply-chain resilience matters to the bioeconomy.

How it got here

The people

Ansa's founders are co-inventors on a combined nine to eleven patent families in enzymatic DNA synthesis. The leadership team pairs that scientific depth with operators drawn from QIAGEN, Thermo Fisher, GeneArt, and Inscripta.